{"nct_id":"NCT00784836","title":"Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients","status":"TERMINATED","status_verified_date":"2014-04","start_date":"2008-10","start_date_type":null,"primary_completion_date":"2009-02","primary_completion_date_type":"ACTUAL","completion_date":"2009-02","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["BIIB"]}